跳至主要内容
临床试验/NCT03189576
NCT03189576进行中(未招募)不适用

Measuring Molecular Residual Disease in Colorectal Cancer After Primary Surgery and Resection of Metastases

Tampere University Hospital2 个研究点 分布在 1 个国家目标入组 37 人开始时间: 2015年10月1日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
37
试验地点
2
主要终点
ctDNA level

研究概览

简要总结

Circulating tumour DNA (ctDNA) is a promising tool when monitoring the residual disease in colorectal cancer (CRC). Current staging procedures are insufficient to identify the patient cohort at high risk, who might benefit from additional adjuvant therapy.

We will show that the assessment of ctDNA is a non-invasive approach and easily taken at different time points via simple blood draw to monitor residual disease from the colorectal cancer patients after primary surgery. Minimal residual disease could be used in the future for individualized treatment decisions after primary surgery.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Diagnostic
盲法
None

入排标准

性别
All
接受健康志愿者

入选标准

  • planned colorectal primary surgery

排除标准

  • unfit patients with dementia

结局指标

主要结局

ctDNA level

时间窗: 3-6 months

residual disease measured by sequential blood draws

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Pirkko-Liisa Kellokumpu-Lehtinen

professor

Tampere University Hospital

研究点 (2)

Loading locations...

相似试验

Measuring Molecular Residual Disease in Colorectal... | 临床试验